3rd Jul 2014 09:33
LONDON (Alliance News) - Horizon Discovery Group PLC said Thursday it has inked a non-exclusive licence agreement with Stanford University in California to use intellectual property related to a proprietary serotype of adeno-associated Virus for gene editing.
The adeno-associated virus is a small virus that is not currently known to cause disease, which means it can be used for gene therapy.
The artificial serotype, created by Mark Kay, infects a broader range of mammalian cells than any naturally occurring version which will allow it to target an increased range of cell types, Horizon said.
"Horizon is committed to ensuring our customers are supported by the widest range of gene editing tools secured by appropriate licenses, enabling us to offer the most complete suite of gene editing products and services to meet their needs," said Chief Technology Officer Eric Rhodes.
Shares in Horizon were trading down 0.7% at 109.25 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
HZD.L